Yahoo Finance

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines ...
Seeking Alpha

Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials ...

Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes ...
News Medical

Study finds a column containing a Galanthus nivalis agglutinin affinity resin can bind all the major COVID-19 variants

In a recent study published in PLoS ONE, researchers assessed the binding of Galanthus nivalis agglutinin to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Study: Removal of ...
News Medical

Study explains the structural basis of higher ACE2 binding affinity of Omicron sub-variants

A team of scientists from China has recently deciphered the structural basis of comparatively higher binding affinity of two Omicron sub-variants, namely B.1.1 and B.2, for human ...
ascopubs.org

Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line ...

A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. This is an ASCO Meeting ...